ABSI
Absci Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+79/100
Last price
10.38
▼ 1.15 (9.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.29
Prev close
11.53
Day high
11.89
Day low
10.21
Volume
5.88M
Market cap
$1.76B
P/E (TTM)
—
52W range
2.24 – 12.06
Day trading desk
Gap from prior close
-10.75%
Prior close 11.53
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
2.70%
10.27 – 10.55
Position in range
40%
Mid range
ATR (14D)
0.99
9.51% of price
Prior day high
11.80
PDH
Prior day low
10.87
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 3.43M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.28%
-0.7%
1M
+16.44%
+15.3%
3M
-7.48%
-12.0%
6M
+251.71%
+233.5%
YTD
+194.27%
+180.0%
1Y
+203.85%
+187.4%
3Y
+678.03%
+595.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ABSI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
20.32M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | SZELA MARY T. Director |
BUY | 12.90K | $148.87K | Direct |
| Jun 4, 26 | SIROSH JOSEPH Director |
STOCK | 10.10K | $0 | Direct |
| Jun 4, 26 | MCGINNIS KAREN K Director |
STOCK | 10.10K | $0 | Direct |
| Jun 4, 26 | RABINOVITSJ DANIEL A Director |
STOCK | 10.10K | $0 | Direct |
| Jun 4, 26 | SZELA MARY T. Director |
STOCK | 10.10K | $0 | Direct |
| Jun 4, 26 | SZELA MARY T. Director |
STOCK | 8.40K | $0 | Direct |
| Jun 4, 26 | VAN HOUTEN FRANS Director |
STOCK | 10.10K | $0 | Direct |
| Jun 4, 26 | PANGALOS MENELAS N Director |
STOCK | 10.10K | $0 | Direct |
| May 13, 26 | PANGALOS MENELAS N Director |
BUY | 37.45K | $200.75K | Direct |
| Mar 12, 26 | BUSCH ANDREAS Officer |
BUY | 100.00K | $229.00K | Direct |
| Mar 2, 26 | MCCLAIN SEAN Chief Executive Officer |
STOCK | 406.20K | $0 | Direct |
| Mar 2, 26 | MCCLAIN SEAN Chief Executive Officer |
STOCK | 406.20K | $0 | Direct |
| Mar 2, 26 | BEDRICK TODD Officer |
STOCK | 49.60K | $0 | Direct |
| Mar 2, 26 | BEDRICK TODD Officer |
STOCK | 49.60K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEDRICK TODD |
Officer | 216.94K | Stock Award(Grant) |
BUSCH ANDREAS |
Officer | 421.45K | Purchase |
JONASSON ZACHARIAH |
Chief Financial Officer | 499.78K | Stock Award(Grant) |
MCCLAIN SEAN |
Chief Executive Officer | 8.72M | Stock Award(Grant) |
MCGINNIS KAREN K |
Director | 48.42K | Stock Award(Grant) |
PANGALOS MENELAS N |
Director | 242.41K | Stock Award(Grant) |
RABINOVITSJ DANIEL A |
Director | 33.42K | Stock Award(Grant) |
SIROSH JOSEPH |
Director | 33.42K | Stock Award(Grant) |
VAN HOUTEN FRANS |
Director | 73.42K | Stock Award(Grant) |
WALKER SHELBY J |
Officer | 139.78K | Stock Award(Grant) |
Fundamentals
Market cap$1.76B
Enterprise value$1.57B
Revenue (TTM)$1.56M
Gross profit$-84.23M
EBITDA$-119.51M
Net income$-121.08M
EPS (TTM)$-0.79
Free cash flow$-50.59M
Total cash$201.14M
Total debt$3.83M
Book value / share$1.44
Shares outstanding171.61M
Float163.79M
Short % of float26.41%
Dividend yield0.00%
Beta (5Y)2.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.21
PEG ratio—
Price / sales—
Price / book7.16
EV / revenue1,002.67
EV / EBITDA-13.10
Gross margin0.00%
Operating margin-10741.51%
Profit margin0.00%
Return on equity-57.72%
Return on assets-34.09%
Debt / equity1.56
Current ratio10.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.80M | $4.53M | $5.72M | $5.75M | -38.2% |
| Operating revenue | $2.80M | $4.53M | $5.72M | $5.75M | -38.2% |
| Research & development | $81.42M | $63.86M | $48.07M | $58.91M | +27.5% |
| Selling, general & admin | $35.06M | $36.17M | $37.83M | $40.55M | -3.1% |
| Total operating expense | $128.22M | $113.42M | $99.90M | $112.50M | +13.0% |
| Operating income | -$125.42M | -$108.89M | -$94.18M | -$106.75M | -15.2% |
| Net interest income | -$209.00K | -$565.00K | -$1.01M | -$972.00K | +63.0% |
| Pre-tax income | -$115.11M | -$103.04M | -$110.47M | -$105.36M | -11.7% |
| Tax provision | $69.00K | $70.00K | $100.00K | -$461.00K | -1.4% |
| Net income | -$115.18M | -$103.11M | -$110.57M | -$104.90M | -11.7% |
| Net income to common | -$115.18M | -$103.11M | -$110.57M | -$104.90M | -11.7% |
| Basic EPS | -0.84 | -0.94 | -1.20 | -1.15 | +10.6% |
| Diluted EPS | -0.84 | -0.94 | -1.20 | -1.15 | +10.6% |
| EBIT | -$114.91M | -$102.47M | -$109.46M | -$104.39M | -12.1% |
| EBITDA | -$103.16M | -$89.08M | -$95.46M | -$91.29M | -15.8% |
| Basic shares | 136.78M | 110.24M | 92.03M | 90.85M | +24.1% |
| Diluted shares | 136.78M | 110.24M | 92.03M | 90.85M | +24.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.02M | $41.21M | $72.36M | $59.95M | — | -51.4% |
| Cash & short-term investments | $144.29M | $112.42M | $97.66M | $164.43M | — | +28.3% |
| Accounts receivable | — | $0 | $2.19M | — | — | — |
| Total current assets | $149.57M | $133.83M | $120.58M | $186.86M | — | +11.8% |
| Property, plant & equipment | $23.77M | $33.13M | $45.82M | $58.04M | — | -28.3% |
| Goodwill & intangibles | $41.51M | $44.88M | $48.25M | $72.96M | — | -7.5% |
| Total assets | $216.30M | $213.61M | $217.30M | $321.01M | — | +1.3% |
| Total current liabilities | $22.77M | $28.66M | $29.56M | $30.27M | — | -20.6% |
| Current debt | $873.00K | $2.73M | $3.26M | $2.95M | — | -68.1% |
| Long-term debt | — | $1.26M | $4.66M | $7.98M | $1.12M | — |
| Total debt | $5.30M | $10.03M | $15.88M | $22.98M | — | -47.1% |
| Total liabilities | $26.85M | $34.48M | $41.12M | $46.59M | — | -22.1% |
| Retained earnings | -$624.78M | -$509.60M | -$406.50M | -$295.93M | — | -22.6% |
| Shareholder equity | $189.45M | $179.13M | $176.18M | $274.41M | — | +5.8% |
| Working capital | $126.81M | $105.17M | $91.02M | $156.59M | — | +20.6% |
| Net tangible assets | $147.94M | $134.25M | $127.92M | $201.46M | — | +10.2% |
| Shares issued | 151.52M | 115.36M | 93.09M | 92.41M | — | +31.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$115.18M | -$103.11M | -$110.57M | -$104.90M | -11.7% |
| Depreciation & amortisation | $11.74M | $13.39M | $14.00M | $13.10M | -12.3% |
| Stock-based compensation | $18.32M | $19.45M | $11.42M | $12.54M | -5.8% |
| Change in working capital | $423.00K | -$368.00K | $1.52M | -$1.54M | +214.9% |
| Operating cash flow | -$92.92M | -$72.40M | -$64.64M | -$81.34M | -28.3% |
| Capital expenditure | -$1.11M | -$404.00K | -$860.00K | -$16.18M | -174.0% |
| Investing cash flow | -$50.16M | -$41.58M | $81.94M | -$126.98M | -20.6% |
| Financing cash flow | $105.95M | $82.53M | -$4.48M | $5.24M | +28.4% |
| Free cash flow | -$94.03M | -$72.81M | -$65.50M | -$97.51M | -29.2% |
| End cash position | $21.08M | $58.21M | $89.67M | $76.84M | -63.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $318.00K | $215.00K | $650.00K | $378.00K | $593.00K | +47.9% |
| Operating revenue | $318.00K | $215.00K | $650.00K | $378.00K | $593.00K | +47.9% |
| Research & development | $22.62M | $19.27M | $25.35M | $19.25M | $20.46M | +17.3% |
| Selling, general & admin | $9.16M | $9.06M | $8.62M | $8.44M | $8.53M | +1.2% |
| Total operating expense | $34.48M | $31.06M | $36.79M | $30.53M | $31.99M | +11.0% |
| Operating income | -$34.16M | -$30.85M | -$36.14M | -$30.15M | -$31.39M | -10.7% |
| Net interest income | -$2.00K | -$18.00K | -$29.00K | -$45.00K | -$56.00K | +88.9% |
| Pre-tax income | -$33.17M | -$29.58M | -$29.72M | -$28.60M | -$30.44M | -12.1% |
| Tax provision | $40.00K | $18.00K | -$162.00K | $104.00K | $131.00K | +122.2% |
| Net income | -$33.21M | -$29.60M | -$29.56M | -$28.71M | -$30.57M | -12.2% |
| Net income to common | -$33.21M | -$29.60M | -$29.56M | -$28.71M | -$30.57M | -12.2% |
| Basic EPS | -0.21 | -0.19 | -0.20 | -0.20 | -0.24 | -10.5% |
| Diluted EPS | -0.21 | -0.19 | -0.20 | -0.20 | -0.24 | -10.5% |
| EBIT | -$33.17M | -$29.56M | -$29.70M | -$28.56M | -$30.38M | -12.2% |
| EBITDA | -$30.47M | -$26.84M | -$26.87M | -$25.71M | -$27.38M | -13.6% |
| Basic shares | 157.47M | 152.96M | 150.61M | 143.77M | 127.59M | +2.9% |
| Diluted shares | 157.47M | 152.96M | 150.61M | 143.77M | 127.59M | +2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $107.86M | $8.63M | $20.02M | $9.48M | $38.02M | — | +1,150.3% |
| Cash & short-term investments | $201.14M | $125.70M | $144.29M | $152.47M | $117.46M | — | +60.0% |
| Accounts receivable | — | — | — | $1.00M | $700.00K | $1.38M | — |
| Total current assets | $208.27M | $131.97M | $149.57M | $174.99M | $137.40M | — | +57.8% |
| Property, plant & equipment | $19.16M | $21.41M | $23.77M | $26.21M | $27.52M | — | -10.5% |
| Goodwill & intangibles | $40.05M | $40.77M | $41.51M | $42.36M | $43.20M | — | -1.8% |
| Total assets | $268.92M | $195.59M | $216.30M | $244.99M | $209.89M | — | +37.5% |
| Total current liabilities | $19.60M | $20.03M | $22.77M | $29.71M | $31.32M | — | -2.2% |
| Current debt | $150.00K | $413.00K | $873.00K | $1.31M | $1.99M | — | -63.7% |
| Long-term debt | — | — | — | $65.00K | $161.00K | $682.00K | — |
| Total debt | $3.83M | $4.42M | $5.30M | $6.22M | $7.41M | — | -13.3% |
| Total liabilities | $22.79M | $23.62M | $26.85M | $34.65M | $36.52M | — | -3.5% |
| Retained earnings | -$687.59M | -$654.38M | -$624.78M | -$595.22M | -$566.52M | — | -5.1% |
| Shareholder equity | $246.13M | $171.97M | $189.45M | $210.34M | $173.37M | — | +43.1% |
| Working capital | $188.67M | $111.94M | $126.81M | $145.29M | $106.08M | — | +68.5% |
| Net tangible assets | $206.08M | $131.20M | $147.94M | $167.98M | $130.18M | — | +57.1% |
| Shares issued | 171.56M | 155.35M | 151.52M | 149.75M | 127.68M | — | +10.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$33.21M | -$29.60M | -$29.56M | -$28.71M | -$30.57M | — | -12.2% |
| Depreciation & amortisation | $2.70M | $2.73M | $2.83M | $2.84M | $3.00M | — | -1.2% |
| Stock-based compensation | $5.24M | $4.38M | $4.26M | $4.40M | $4.75M | — | +19.7% |
| Change in working capital | -$1.74M | -$3.13M | -$801.00K | -$2.73M | $6.74M | — | +44.3% |
| Operating cash flow | -$27.56M | -$26.31M | -$29.18M | -$25.03M | -$16.87M | — | -4.8% |
| Capital expenditure | -$1.00K | -$30.00K | — | -$962.00K | -$223.00K | -$25.00K | +96.7% |
| Investing cash flow | $24.07M | $7.36M | $19.55M | -$63.70M | $9.04M | — | +226.9% |
| Financing cash flow | $102.73M | $7.56M | $3.84M | $60.32M | -$1.00M | — | +1,259.5% |
| Free cash flow | -$27.57M | -$26.34M | -$29.08M | -$25.99M | -$17.10M | — | -4.7% |
| End cash position | $108.92M | $9.69M | $21.08M | $26.87M | $55.29M | — | +1,024.2% |
Options analytics
Put / call volume
0.38
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-90.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
626
Contracts, this expiry
Put volume
236
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
6.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.21 | -6.4% |
| Mar 2026 | -0.20 | -0.19 | +4.6% |
| Dec 2025 | -0.17 | -0.23 | -32.5% |
| Sep 2025 | -0.21 | -0.20 | +2.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.20 | 7 | $646.33K | +71.0% |
| Next quarter | -0.20 | 7 | $1.12M | +72.3% |
| Current year | -0.81 | 7 | $3.89M | +39.0% |
| Next year | -0.68 | 7 | $16.00M | +310.9% |
Analyst targets & ownership
Mean target$14.40
High target$17.00
Low target$10.00
Implied upside38.73%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 8
Hold1
Sell / Strong sell0 / 0
Held by insiders11.84%
Held by institutions87.31%
Institutions holding263
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.39
-0.05% from price
SMA 20
9.62
+6.72% from price
SMA 50
9.13
+12.50% from price
SMA 100
8.53
+21.70% from price
SMA 200
5.94
+73.01% from price
EMA 12
10.31
+0.69% from price
EMA 26
9.79
+6.05% from price
EMA 50
9.30
+11.61% from price
RSI (14)
54.1
Neutral
MACD (12,26,9)
0.52
Hist 0.13
ATR (14)
0.99
9.61% of price
Realised vol 30D
87.7%
Annualised
Bollinger upper
11.79
20, 2σ
Bollinger lower
7.46
20, 2σ
50 / 200 cross
Golden
9.13 vs 5.94
Trend bias
Above 200
+73.01%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.29
More volatile than market
Correlation to SPY
0.41
Loosely linked
Realised vol 30D
87.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-54.0%
Peak to trough
Max drawdown 5Y
-93.6%
Peak to trough
ATR 14
0.99
9.61% of price
Beta (reported)
2.28
5Y monthly, from filing
Short interest
Shares short
37.26M
Prior 37.42M
Change vs prior
-0.4%
Shorts covering
% of float
26.41%
Heavily shorted
% of shares out
21.71%
Against total outstanding
Days to cover
13.3
Crowded exit
Float
163.79M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 9, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Sep 8, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 12, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 2, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jun 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 24, 26 | Needham | MAINTAINED | Buy | Buy |
| Jun 24, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 15, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 4, 26 | Leerink Partners | INITIATED | — | Outperform |
| May 28, 26 | BTIG | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-22
Offering Registrations
S-8 · 2026-03-24
Corporate Changes & Voting Matters
8-K · 2026-03-06
Corporate Changes & Voting Matters
8-K · 2026-01-14
Headlines
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
MT Newswires · 13d ago
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
GlobeNewswire · 13d ago
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Simply Wall St. · 15d ago
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
MarketBeat · 16d ago
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Insider Monkey · 25d ago
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
CNW Group · 34d ago
Absci to Participate in Upcoming Investor Conferences
GlobeNewswire · 36d ago
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
BeInCrypto · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.